{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:15:43Z","timestamp":1775060143202,"version":"3.50.1"},"reference-count":24,"publisher":"Scientific Scholar","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"\n Background & objectives:<\/jats:title>\n Adriamycin though considered as an effective anticancer drug, leads to irreversible cardiomyopathy (CMP) and congestive heart failure (CHF). The aim of this study was to determine the protective effect of carvedilol in adriamycin (ADR)-induced cardiomyopathy (CMP) in cancer patients.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Patients with lymphoreticular malignancy in whom ADR therapy was planned were randomized into two groups: carvedilol and control. Twenty seven patients each were enrolled in carvedilol and control groups. In the carvedilol group, 12.5 mg once daily oral carvedilol was given during six months. The patients were evaluated by echocardiography before and after chemotherapy. Left ventricular ejection fraction (EF) and systolic and diastolic diameters were calculated.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n At six months of follow up, six patients in the carvedilol group and five in the control group had died. The mean EF (63.19 vs. 63.88%) and fraction shortening (FS) (34 vs. 34.6) of the carvedilol group were similar at follow up, but in the control group, the mean EF (67.27 vs. 60.82%, P<\/jats:italic>=0.003) and FS (38.48 vs. 34.6, P<\/jats:italic><0.05) at control echocardiography were significantly lower. In carvedilol group, both systolic and diastolic diameters were not changed, but in control group, systolic diameters were significantly increased compared with basal measures (left ventricular end systolic diameter = 28.26\u00b15.50 mm vs. 31.25\u00b1 6.50 mm; P<\/jats:italic>< 0.05).<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions:<\/jats:title>\n Prophylactic use of carvedilol in patients receiving anthracycline protected systolic functions of the left ventricle. Carvedilol can be a potential drug which can ameliorate ADR-induced CMP.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_1323_14","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T13:12:30Z","timestamp":1490965950000},"page":"725-729","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Preventive role of carvedilol in adriamycin-induced cardiomyopathy"],"prefix":"10.25259","volume":"144","author":[{"given":"Rajesh","family":"Jhorawat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savita","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhash C.","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj K.","family":"Rohit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Narula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Suri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"R1-14-20241212","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin Oncol"},{"key":"R2-14-20241212","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience","volume":"15","author":"Krischer","year":"1997","journal-title":"J Clin Oncol"},{"key":"R3-14-20241212","doi-asserted-by":"crossref","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"R4-14-20241212","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0005-2728(70)90149-0","article-title":"The role of GSH peroxidase in protecting the membrane of rat liver mitochondria","volume":"223","author":"Floh\u00e9","year":"1970","journal-title":"Biochim Biophys Acta"},{"key":"R5-14-20241212","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0009-2797(77)90050-3","article-title":"Adriamycin stimulated superoxide formation in submitochondrial particles","volume":"19","author":"Thayer","year":"1977","journal-title":"Chem Biol Interact"},{"key":"R6-14-20241212","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1172\/JCI109642","article-title":"Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin","volume":"65","author":"Doroshow","year":"1980","journal-title":"J Clin Invest"},{"key":"R7-14-20241212","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R8-14-20241212","first-page":"535","article-title":"The protective effect of melatonin on adriamycin-induced acute cardiac injury","volume":"19","author":"Ko\u00e7ak","year":"2003","journal-title":"Can J Cardiol"},{"key":"R9-14-20241212","first-page":"1089","article-title":"Mice primed with swainsonine are protected against doxorubicin-induced lethality","volume":"49","author":"Oredipe","year":"2003","journal-title":"Cell Mol Biol (Noisy-le-grand"},{"key":"R10-14-20241212","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jat.889","article-title":"Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats","volume":"23","author":"Fadillioglu","year":"2003","journal-title":"J Appl Toxicol"},{"key":"R11-14-20241212","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1527-3466.2001.tb00061.x","article-title":"Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential","volume":"19","author":"Cheng","year":"2001","journal-title":"Cardiovasc Drug Rev"},{"key":"R12-14-20241212","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro","volume":"37","author":"Spallarossa","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"R13-14-20241212","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia","volume":"18","author":"El-Shitany","year":"2012","journal-title":"J Card Fail"},{"key":"R14-14-20241212","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R15-14-20241212","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/cvr\/28.3.400","article-title":"Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils","volume":"28","author":"Yue","year":"1994","journal-title":"Cardiovasc Res"},{"key":"R16-14-20241212","first-page":"27","article-title":"Carvedilol, a new beta adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes","volume":"1","author":"Yue","year":"1992","journal-title":"Pharmacol Commun"},{"key":"R17-14-20241212","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0014-2999(92)90130-V","article-title":"Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils","volume":"214","author":"Yue","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"R18-14-20241212","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/00004872-199306003-00010","article-title":"Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity","volume":"11","author":"Feuerstein","year":"1993","journal-title":"J Hypertens Suppl"},{"key":"R19-14-20241212","first-page":"1291","article-title":"Advantages in the use of carvedilol versus propranolol for the protection of cardiac mitochondrial function","volume":"23","author":"Oliveira","year":"2004","journal-title":"Rev Port Cardiol"},{"key":"R20-14-20241212","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/01.CIR.100.4.346","article-title":"Effect of beta-blockers on free radical-induced cardiac contractile dysfunction","volume":"100","author":"Flesch","year":"1999","journal-title":"Circulation"},{"key":"R21-14-20241212","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"R22-14-20241212","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R23-14-20241212","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000343622","article-title":"Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial","volume":"123","author":"Heck","year":"2012","journal-title":"Cardiology"},{"key":"R24-14-20241212","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur J Cancer"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201644050-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:58:37Z","timestamp":1751497117000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/preventive-role-of-carvedilol-in-adriamycin-induced-cardiomyopathy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_1323_14","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}